AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q4 FY20 results · Jan–Mar 2020
AstraZeneca Pharma India reported revenue from operations of ₹194.90 crore (up 2.4% from Q4 FY19) and net profit of ₹9.58 crore (down 2.5% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a standalone basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 194.90 | 190.30 | +2.4% | 223.86 | −12.9% |
| Other income | 3.38 | 6.01 | −43.8% | 3.46 | −2.5% |
| Total income | 198.28 | 196.31 | +1.0% | 227.32 | −12.8% |
| Profit before tax | 13.35 | 8.47 | +57.6% | 35.18 | −62.0% |
| Net profit for the period | 9.58 | 9.82 | −2.5% | 26.70 | −64.1% |
| EPS, basic (₹) | 3.83 | 3.93 | −2.5% | 10.68 | −64.1% |
| Net margin (%) | 4.9 | 5.2 | 11.9 |
Standalone
- Filed with BSE
- 19 May 2020, 14:51 IST
- Board meeting
- 18 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE